2024 annual meeting
Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories
May 11, 2024, 8:30 a.m. US/Eastern
In person at Boston Marriott Cambridge
Register Now
May 11, 2024, 8:30 a.m. US/Eastern
In person at Boston Marriott Cambridge
Register Now
Welcome to the 2024 Annual Conference of the Chinese Antibody Society (CAS), set to take place in Cambridge, MA, USA, on Saturday, May 11, 2024. This year's theme, "Beyond Borders: Advancements in Antibody-Based Therapeutics in Uncharted Territories," aims to spotlight the latest breakthroughs in therapeutic antibodies, alongside innovative approaches in their discovery, development, and manufacturing.
Sponsorship Opportunities
The 2024 Annual Conference sponsorship drive is in full swing, offering Title and Premium sponsorship categories, each with distinct benefits and services. This year, we are excited to offer six unique naming opportunities (dinner, lunch, name badges, WiFi, tea breaks, and posters), with Title sponsors enjoying exclusive naming rights in addition to Premium category benefits. Interested sponsors are encouraged to reach out at sponsor@chineseantibody.org for more information.
Conference Details
Date and Venue:
- Saturday, May 11, 2024
- Boston Cambridge Marriott Hotel, 50 Broadway, Cambridge, MA 02142, USA
Registration Information:
- Academia (students, post-docs, research associates, etc.) Conference only: $15
- Member Conference only: $30
- Non-member Conference only: $50
- Academia Conference + Dinner: $100
- Member Conference + Dinner: $100
- Non-member Conference + Dinner: $150
Chinese Antibody Society members will enjoy discount on registration fees. To become a member, please visit https://chineseantibody.org.
Please be aware that while we do accommodate on-site registrations, the fees for registering on-site will differ from those for pre-registrations. We recommend registering early due to limited seating for both the conference and the dinner event. Registration will close automatically once capacity is reached.
Join Us
We cordially invite you to the 2024 Annual CAS Conference. Stay tuned for updates on the CAS official website, LinkedIn, and our WeChat account.
We are delighted to invite you to submit your work for the poster session at the 2024 Chinese Antibody Society Annual Conference. We welcome contributions across a broad spectrum of topics within the field of therapeutic antibodies. Submissions can include, but are not limited to, innovations in modalities, breakthrough technologies in the discovery, development, and manufacturing of antibody drugs, as well as the latest advancements in production processes and clinical updates.
To have your poster reviewed by our committee to get the award, please submit your poster abstract by March 17, 2024, at https://www.casconferenceposter.org/. Please ensure that your submission is in its final version. Abstracts should be in English, contain less than 500 words, and be formatted in plain text, excluding figures or tables. Selected abstracts for poster presentation will be eligible to include figures and/or tables in the final poster.
For any further inquiries or questions, do not hesitate to reach out to us at conference@chineseantibody.org.
We look forward to receiving your insightful contributions and to fostering engaging discussions at the conference.
Awards
• The authors of the top 20 (approximately) abstracts will receive an award certificate and an invitation to present their posters at the society's 2024 Annual Conference.
• Authors of the top abstracts will be invited for a 10-minute presentation at the conference and awarded a certificate of recognition. They are required to attend the conference in person, and the Chinese Antibody Society will offer a travel award to assist with travel expenses.
Hover above speaker cards to read bio
Gordon Freeman
(Keynote Speaker) Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School
Mitchell Ho
Editor-in-Chief, Antibody therapeutics and Senior Investigator, NIH
Zhiqiang An
Vice President of Drug Discovery, UTHealth Houston
Cheng Liu
Founder, President and CEO, Eureka Therapeutics
Janice Reichert
COO, The Antibody Society
Yu Qiu
Head of AI Innovation, Large Molecule Research, Sanofi
Man Hee Suh
CTO, Kactus
Marie Zhu
CTO, Wuxi XDC
Yang Liu
Founder, Chairman and CEO, OncoC4
Starts at 05/11/2024 8:30 a.m. US/Eastern
Hover to view abstract
05/11/2024 8:30 a.m. US/Eastern
Opening Remarks
Jingsong Wang, Chairman and CEO, Harbour BioMed
05/11/2024 9 a.m. US/Eastern
Announcements and Overview of Chinese Antibody Society
Bo Liu, Co-founder and President, Umabs Therapeutics
05/11/2024 9:30 a.m. US/Eastern
Keynote lecture: Cancer Immunotherapy
Gordon Freeman, (Keynote Speaker) Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School
05/11/2024 10 a.m. US/Eastern
Accelerating Cure of Cancer by Antibody-Guided T Cell Therapy: An Alternative Strategy from CAR-T or TCR-T
Cheng Liu, Founder, President and CEO, Eureka Therapeutics
05/11/2024 10:30 a.m. US/Eastern
Learning “Grammars” and “Semantics” by Protein Language Models (PLMs)
Yu Qiu, Head of AI Innovation, Large Molecule Research, Sanofi
05/11/2024 11 a.m. US/Eastern
Developing Antibodies Targeting LILRB2/TREM2 in Alzheimer’s Disease
Zhiqiang An, Vice President of Drug Discovery, UTHealth Houston
05/11/2024 1:35 p.m. US/Eastern
Quantifying the Success of Antibody Therapeutics
Janice Reichert, COO, The Antibody Society
05/11/2024 2:05 p.m. US/Eastern
Superior Payload-linker and Conjugation Technologies for Novel and Better ADCs
Marie Zhu, CTO, Wuxi XDC
05/11/2024 2:35 p.m. US/Eastern
Engineering Complex Antigens for Biopharma Industry: Major Histocompatibility Complexes and Multipass
Man Hee Suh, CTO, Kactus
05/11/2024 3:05 p.m. US/Eastern
CD24-Siglec Pathway in Cancer Therapy
Yang Liu, Founder, Chairman and CEO, OncoC4
05/11/2024 3:35 p.m. US/Eastern
Generation of Camel and Shark Nanobodies Neutralizing SARS-CoV-2 and Lassa Virus
Mitchell Ho, Editor-in-Chief, Antibody therapeutics and Senior Investigator, NIH
05/11/2024 4:05 p.m. US/Eastern
Closing Remarks
Mitchell Ho, Editor-in-Chief, Antibody therapeutics and Senior Investigator, NIH
